Instituut voor Neuropathische Pijn

Wij onderschrijven de gedragscode van de Health On the Net Foundation
Home arrow Algemeen arrow Wetenschap arrow Chronische pijnindicaties palmitoylethanolamide
Chronische pijnindicaties palmitoylethanolamide
mast_cell_glia_cell_nerve_cell.gif

Palitoylethanolamide (merknaam Normast®) werkt op drie belangrijke cellen die alledrie een sleutelrol spelen bij chronische pijnsyndromen, namelijk 

  1. op de zenuwcel, 
  2. de gliacel en 
  3. de mestcel. 
Hiernaast een afbeelding van deze drie cellen. De mestcel is de grote rode gebobbelde cel. In die bobbels zitten allemaal stofjes die als ze vrijkomen de glia cellen, de bruine cellen, en de zenuwcellen, de zwarte cellen overspannen maken. Dan en daardoor maken de zenuwcellen en de glia cellen elkaar ook gek.
 
Hieronder een niet uitputtende lijst van inicaties binnen de chronische pijnsyndromen waar palmitoylethanolamide een therapeutische rol bij kan spelen, en de literatuur die dat ondersteunt. Deze lijst is met name bedoeld voor intercollegiale consulten, overleg met de artsen die ons instituut raadplegen over de behandeling van bepaalde pijnsyndromen.

Chronische pijnsyndromen

Algemene chronische pijnsyndromen [1] [2] [3] [4] [5] [4][7][8][9][10][11][12]

Hernia pijn [13]

Diabetische neuropathische pijnen [14] [15]

Herpes zosterpijn [16]

Neuropathische pijnen bij CIAP, CIDP, etc [8]

Carpaal tunnelsyndroom [18]

Regionaal chronisch pijnsyndroom, Sudeck [19]

Pijn en pijnlijke spasmen in MS [20] [21] [22] [23] [24][25] [26][27][28][29][30]

Centraal neuropathische pijnen door beroerte [31][32][33][34]

Centraal neuropathische pijnen door syringomyelie en dwarslesies [20][36]

Migraine [37] [38] [39][40]

Fibromyalgie [41]

Reumatoide artritis en Bechterew pijnen [42][43][44]

Artritis psoriatica [45]

Syndroom van Costen [46]

Chronische pruritis eci [47]

Pijn en jeuk na chemotherapie [48]


Referenties

[1]: D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, Meli R, Calignano A. | Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. | Eur J Pharmacol. | 2009 Jun 24;613(1-3):54-9. Epub 2009 Apr 20.
[2]: Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L. | Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. | J Cell Mol Med. | 2011 Jan 21. doi: 10.1111/j.1582-4934.2011.01267.x. [Epub ahead of print]
[3]: Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. | Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. | Vet Immunol Immunopathol. | 2010 Jan 15;133(1):9-15. Epub 2009 Jun 27.
[5]: De Filippis D, D'Amico A, Iuvone T. | Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. | J Neuroendocrinol. | 2008 May;20 Suppl 1:20-5.
[7]: Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, Barrett DA, Chapman V. | Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. | Neuropharmacology. | 2008 Jul;55(1):85-93. Epub 2008 Apr 29.
[8]: Wallace VC, Segerdahl AR, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, Hasnie F, Rice AS. | The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. | Br J Pharmacol. | 2007 Aug;151(7):1117-28. Epub 2007 Jun 11.
[9]: LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. | Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. | J Pharmacol Exp Ther. | 2006 Dec;319(3):1051-61. Epub 2006 Sep 22.
[10]: Farquhar-Smith WP, Rice AS. | Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. | Anesthesiology. | 2001 Mar;94(3):507-13; discussion 6A.
[12]: Matzke AJ, Weiger TM, Matzke MA. | Detection of a large cation-selective channel in nuclear envelopes of avian erythrocytes. | FEBS Lett. | 1990 Oct 1;271(1-2):161-4.
[13]: G. Guida, A. de Fabiani, F. Lanaia, A. Alexandre, G.M. Vassallo, L. Cantieri, M. de Martino, M. Rogai, S. Petrosino | La palmitoiletanolamida (Normast) en el dolor neuropatico cronico por lumbociatalgia de tipo compresivo: estudio clinico multicentrico. | Dolor | 2010, 25:35-42
[14]: Biasiotta A, La Cesa S, Leone C, Di Stefano G, Truini A, Cruccu G. | Efficacy of palmitoylethanolamide in patients with painful neuropathy. A clincial and neurophysiological open study. Preliminary results. | , Volume 4, Issue 1, May 2010, Page 77. |
[15]: Matias I, Wang JW, Moriello AS, Nieves A, Woodward DF, Di Marzo V. | Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. | Prostaglandins Leukot Essent Fatty Acids. | 2006 Dec;75(6):413-8. Epub 2006 Oct 2.
[16]: Phan NQ, Siepmann D, Gralow I, Ständer S. | Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. | J Dtsch Dermatol Ges. | 2010 Feb;8(2):88-91. Epub 2009 Sep 10.
[17]: Wallace VC, Segerdahl AR, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, Hasnie F, Rice AS. | The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. | Br J Pharmacol. | 2007 Aug;151(7):1117-28. Epub 2007 Jun 11.
[18]: Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, Ratto S. | P1577: The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide | Eur J Neurol | 2010: 17(S3):295.
[19]: Islam MS, Nilsson T, Rorsman P, Berggren PO. | Interaction with the inositol 1,4,5-trisphosphate receptor promotes Ca2+ sequestration in permeabilised insulin-secreting cells. | FEBS Lett. | 1991 Aug 19;288(1-2):27-9.
[20]: Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. | Brain Behav Immun. | 2011 Feb 25. [Epub ahead of print]
[21]: Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS. | Plasma endocannabinoid levels in multiple sclerosis. | J Neurol Sci. | 2009 Dec 15;287(1-2):212-5. Epub 2009 Aug 20.
[22]: Zajicek JP, Apostu VI. | Role of cannabinoids in multiple sclerosis. | CNS Drugs. | 2011 Mar 1;25(3):187-201. doi: 10.2165/11539000-000000000-00000.
[23]: Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M, Guaza C, Di Marzo V, Docagne F. | Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. | Eur J Neurosci. | 2008 Aug;28(4):633-41. Epub 2008 Jul 24.
[24]: Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J. | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. | Neurobiol Dis. | 2005 Nov;20(2):207-17.
[25]: Maccarrone M, Bernardi G, Agrò AF, Centonze D. | Cannabinoid receptor signaling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. | Br J Pharmacol. | 2011 Feb 16. doi: 10.1111/j.1476-5381.2011.01277.x. [Epub ahead of print]
[26]: Bisogno T, Di Marzo V. | Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. | CNS Neurol Disord Drug Targets. | 2010 Nov;9(5):564-73.
[27]: Correa F, Hernangómez-Herrero M, Mestre L, Loría F, Docagne F, Guaza C. | The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. | Brain Behav Immun. | 2011 May;25(4):736-49. Epub 2011 Feb 16.
[28]: Rossi S, Bernardi G, Centonze D. | The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. | Exp Neurol. | 2010 Jul;224(1):92-102. Epub 2010 Mar 29.
[29]: Loría F, Petrosino S, Hernangómez M, Mestre L, Spagnolo A, Correa F, Di Marzo V, Docagne F, Guaza C. | An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. | Neurobiol Dis. | 2010 Jan;37(1):166-76. Epub 2009 Oct 6.
[30]: Correa FG, Mestre L, Docagne F, Borrell J, Guaza C. | The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. | Vitam Horm. | 2009;81:207-30.
[31]: Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, Pizzolato G, Di Marzo V. | Possible Anandamide and Palmitoylethanolamide involvement in human stroke. | Lipids Health Dis. | 2010 May 14;9:47.
[32]: Hansen HS. | Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. | Exp Neurol. | 2010 Jul;224(1):48-55. Epub 2010 Mar 29.
[33]: Koch M, Kreutz S, Böttger C, Benz A, Maronde E, Ghadban C, Korf HW, Dehghani F. | Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-alpha. | Neurotox Res. | 2011 Feb;19(2):330-40. Epub 2010 Mar 11.
[34]: Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz WR. | Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. | Brain Res. | 2008 Nov 13;1240:213-20. Epub 2008 Sep 18.
[35]: Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. | Brain Behav Immun. | 2011 Feb 25. [Epub ahead of print]
[36]: Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S. | Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. | J Pharmacol Exp Ther. | 2008 Jul;326(1):12-23. Epub 2008 Mar 26.
[37]: Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P. | Endocannabinoids in chronic migraine: CSF findings suggest a system failure. | Neuropsychopharmacology. | 2007 Jun;32(6):1384-90. Epub 2006 Nov 22.
[38]: Levy D. | Migraine pain, meningeal inflammation, and mast cells. | Curr Pain Headache Rep. | 2009 Jun;13(3):237-40.
[39]: Levy D, Burstein R, Strassman AM. | Mast cell involvement in the pathophysiology of migraine headache: A hypothesis. | Headache. | 2006 Jun;46 Suppl 1:S13-8.
[40]: Zhang XC, Strassman AM, Burstein R, Levy D. | Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. | J Pharmacol Exp Ther. | 2007 Aug;322(2):806-12. Epub 2007 May 4.
[41]: Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, Janciauskiene S, Oikonomopoulou K, de Serres FJ, Fernández-Bustillo E, Hollenberg MD. | Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. | Clin Rheumatol. | 2010 Dec;29(12):1403-12. Epub 2010 Apr 30.
[42]: Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. | Mast cells: a cellular link between autoantibodies and inflammatory arthritis. | Science. | 2002 Sep 6;297(5587):1689-92.
[43]: Nigrovic PA, Lee DM. | Mast cells in autoantibody responses and arthritis. | Novartis Found Symp. | 2005;271:200-9; discussion 210-4.
[44]: Christy AL, Brown MA. | The multitasking mast cell: positive and negative roles in the progression of autoimmunity. | J Immunol. | 2007 Sep 1;179(5):2673-9.
[45]: Cañete JD, Celis R, Noordenbos T, Moll C, Gómez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmartí R, Baeten D. | Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. | Arthritis Res Ther. | 2009;11(1):R17. Epub 2009 Feb 6.
[46]: Bortolotti F,Russo M, Bartolucci ML, Alessandri Bonetti G, Gatto MR, Marini I. | Palmitoylethanolamide vs NSAID in the treatment of TMJD Pain | Journal of Dental Research | 2010: 89(Special Issue B)
[47]: Ständer S, Raap U, Weisshaar E, Schmelz M, Mettang T, Handwerker H, Luger TA. | Pathogenesis of pruritus. | J Dtsch Dermatol Ges. | 2011 Jun;9(6):456-463. doi: 10.1111/j.1610-0387.2011.07585.x. Epub 2011 Jan 5.
[48]: Latif S, Fraga G, Gadzia J. | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. | J Drugs Dermatol. | 2010 Mar;9(3):268-70.
 
© Copyright 2012 Instituut voor Neuropathische Pijn. Alle rechten voorbehouden.